| Item type |
学内発行雑誌 / Departmental Bulletin Paper(1) |
| 公開日 |
2018-04-20 |
| タイトル |
|
|
タイトル |
EGFR-TKI Versus Chemotherapy for Previously Untreated Advanced Non-Small Cell Lung Cancer in Asians: A Meta-Analysis |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ |
departmental bulletin paper |
| 著者 |
ANDO, Koichi
KUSUMOTO, Sojiro
TANAKA, Akihiko
YAMAOKA, Toshimitsu
OHMORI, Tohru
OHNISHI, Tsukasa
INOUE, Shin
SAGARA, Hironori
|
| 書誌情報 |
The Showa University journal of medical sciences
巻 29,
号 4,
p. 435-443,
発行日 2017-12
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
We comparatively assessed the overall efficacies of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy for previously untreated, EGFR mutation-positive, advanced non-small cell lung cancer in Asians through a meta-analysis of relevant phase-3 trials. The primary and secondary outcomes were overall survival (OS) and progression-free survival (PFS), respectively. Pooled estimates were calculated as hazard ratios (HRs) with 95% confidence intervals (CIs). Seven studies on EGFR-TKIs met the inclusion criteria for this study. The HRs and 95% CIs for OS and PFS for EGFR-TKIs, relative to chemotherapy, were 0.98 (0.77–1.24) and 0.32 (0.24–0.43), respectively. We found no difference in overall efficacy between EGFR-TKIs and chemotherapy in terms of OS, although the median PFS with EGFR-TKI was superior to that with chemotherapy among Asians with previously untreated, EGFR mutation-positive, advanced non-small cell lung cancer (UMIN ID: UMIN28424). |
| DOI |
|
|
|
関連識別子 |
10.15369/sujms.29.435 |
| 出版者 |
|
|
出版者 |
Showa University Society |
| ISSN |
|
|
収録物識別子 |
0915-6380 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
S29_435.pdf (464.6 kB)
